About
About Parabolic Drugs Limited
Parabolic Drugs Limited develops, manufactures, and sells active pharmaceutical ingredients (API) and API intermediates in India. The company offers oral and sterile semi synthetic penicillin APIs; oral and sterile cephalosporin APIs in antibiotic area; non-antibiotic APIs for cardiovascular, NSAID, anti-hypertensive, and osteoporosis therapeutic areas; and calcium sennoside, colchicine, raubasine, reserpine, thiocolchicoside, vinpocetine, and yohimbine. It also provides custom research and manufacturing services to pharma companies, including research and development, and manufacturing services for NCE and generics; IPR support for process design and infringement guidance; and QA, QC, and regulatory support for meeting quality and documentation requirements. The company also exports its products to approximately 51 countries. Parabolic Drugs Limited was founded in 1996 and is based in Chandigarh, India.
Visit company website
5 years, 4 months ago
Parabolic Drugs Limited is currently in a long term uptrend where the price is trading 18.6% above its 200 day moving average.
From a valuation standpoint, the stock is 95.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.2.
Its net income has increased by 16.2% to $-60M since the same quarter in the previous year.
Finally, its free cash flow fell by 0.0% to $-1M since the same quarter in the previous year.
Based on the above factors, Parabolic Drugs Limited gets an overall score of 3/5.